Protein Supplementation in Hyponatremia Due to the Syndrome of Inappropriate Antidiuresis
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital, Basel, Switzerland
About this trial
The goal of this study is to assess the impact of protein supplementation on hyponatremia caused by the syndrome of inappropriate antidiuresis during hospitalization.
Eligibility criteria
Qualifiers
Plasma sodium concentration <135 mmol/L
Plasma osmolality <300 mOsm/kg
Urine osmolality >100 mOsm/kg
Urine sodium concentration >30 mmol/L
Disqualifiers
Lactose intolerance, milk protein allergy, soy allergy, nuts allergy, or hypersensitivity to components of the protein supplement.
Inborn metabolic disorders affecting carbohydrate, lipid, or protein metabolism.
Severe symptomatic hyponatremia requiring 3% NaCl or intensive care.
New (within the last five days) treatment with SGLT2 inhibitors, vaptans or oral urea
Trial design
Treatments tested in this trial
- Moltein PURE Protein Powder
- Fluid restriction
Treatment groups
70 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov